CONTROVERSIA

This profile has not been translated into English yet. It is shown in French, the reference language (automatic translation tools in your browser can help). Legal statuses and counts are shown in English.

Portrait of Thermo Fisher Scientific

Portrait: Wikimedia Commons search — See Wikimedia Commons source page · source

Sciences de la vie / instrumentation / diagnostics / services biopharma et recherche clinique

Thermo Fisher Scientific

Fiche documentée couvrant 20 controverses, dont « Constitution de Thermo Electron » et « Introduction en Bourse de Thermo Electron ».

Your opinion of this profile

Profile No. 5162 · Updated on 26 September 2026

20Documented controversies
16Sources
0Formal charge · all time
0Conviction

§ Legal statuses reflect the documented sources as of the date shown; they replace neither court decisions nor the presumption of innocence. Counts are not a rating. Methodology

I. Documented controversies

01

24 mars 2026

Acquisition de Clario Holdings

Status not specified

Not yet available in English — French original shown.

Thermo Fisher finalise l’acquisition de Clario pour 8,875 Md$ en numéraire, plus paiements potentiels, ajoutant des solutions de données de critères d’évaluation pour essais cliniques.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Thermo Fisher ScientificThermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.Very high reliability

Last verified: 21 September 2026

02

17 juillet-7 août 2026

Rappel FDA Class II de certains lots d’antisérum Neisseria meningitidis groupe C

Status not specified

Not yet available in English — French original shown.

Remel Europe Ltd., entité du périmètre Thermo Fisher Diagnostics, lance un rappel de certains lots d’antisérum Neisseria meningitidis groupe C après constat qu’ils ne satisfaisaient pas au critère de performance prévu par la notice pour la souche ATCC13102.

Sources · 1

  1. [1]
    U.S. Food and Drug AdministrationClass 2 Device Recall Thermo Fisher DiagnosticsVery high reliability

Last verified: 21 September 2026

03

1er septembre 2025

Acquisition de l’activité Purification & Filtration de Solventum

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert l’activité Purification & Filtration de Solventum pour environ 4,0 Md$ après exclusion de l’activité filtration d’eau potable du périmètre initial.

Legal status — source text
completed

Sources · 1

  1. [1]
    SolventumSolventum Completes Sale of Purification & Filtration Business to Thermo FisherVery high reliability

Last verified: 21 September 2026

04

10 juillet 2024

Acquisition d’Olink

Status not specified

Not yet available in English — French original shown.

Thermo Fisher finalise l’acquisition d’Olink, spécialiste de protéomique de nouvelle génération, pour une valeur d’environ 3,1 Md$ net de trésorerie acquise.

Legal status — source text
completed

Sources · 1

  1. [1]
    Thermo Fisher ScientificThermo Fisher Scientific Completes Acquisition of OlinkVery high reliability

Last verified: 21 September 2026

05

2023

Acquisitions de The Binding Site et CorEvitas

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert The Binding Site dans les diagnostics de myélome et CorEvitas dans les données de vie réelle réglementaires.

Legal status — source text
completed

Sources · 2

  1. [1]
    Thermo Fisher ScientificThermo Fisher Scientific Completes Acquisition of The Binding Site GroupVery high reliability
  2. [2]
    Thermo Fisher ScientificThermo Fisher Scientific Completes Acquisition of CorEvitasVery high reliability

Last verified: 21 September 2026

06

25 février 2021

Acquisition de Mesa Biotech

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert Mesa Biotech, plateforme PCR rapide au point de soin, pour une contrepartie en numéraire et conditionnelle.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific Q1 2021 Form 10-QVery high reliability

Last verified: 21 September 2026

07

8 décembre 2021

Acquisition de PPD

Status not specified

Not yet available in English — French original shown.

Thermo Fisher finalise l’acquisition de PPD pour 17,4 Md$, ajoutant une grande plateforme mondiale de recherche clinique.

Legal status — source text
completed

Sources · 2

  1. [1]
    Thermo Fisher ScientificThermo Fisher Scientific Completes Acquisition of PPD, Inc.Very high reliability
  2. [2]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific Q3 2021 Form 10-QVery high reliability

Last verified: 21 September 2026

08

mars-août 2020

Offre publique sur QIAGEN puis échec du rapprochement

Status not specified

Not yet available in English — French original shown.

Thermo Fisher conclut un accord pour acquérir QIAGEN, relève ensuite son offre, mais l’offre expire après seulement 47,02 % de titres apportés, sous le seuil requis ; l’accord est résilié et QIAGEN doit verser 95 M$ de remboursement de frais.

Legal status — source text
terminated

Sources · 1

  1. [1]
    Thermo Fisher ScientificThermo Fisher Announces Lapse of Offer to Acquire QIAGENVery high reliability

Last verified: 21 September 2026

09

30 avril 2019

Acquisition de Brammer Bio

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert Brammer Bio pour environ 1,67 Md$, renforçant ses capacités de fabrication de vecteurs viraux pour thérapies géniques et cellulaires.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2019 Annual ReportVery high reliability

Last verified: 21 September 2026

10

28 juin 2019

Cession de l’activité Anatomical Pathology à PHC

Status not specified

Not yet available in English — French original shown.

Thermo Fisher cède son activité Anatomical Pathology à PHC Holdings pour environ 1,13 Md$ net de trésorerie cédée.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2019 Annual ReportVery high reliability

Last verified: 21 September 2026

11

25 octobre 2018

Acquisition de l’activité Advanced Bioprocessing de BD

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert l’activité Advanced Bioprocessing de Becton Dickinson pour 477 M$, élargissant son offre de produits de culture cellulaire.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2019 Annual ReportVery high reliability

Last verified: 21 September 2026

12

février-mars 2017

Acquisitions de Finesse Solutions et Core Informatics

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert Finesse Solutions dans le bioprocess et Core Informatics dans les plateformes de données scientifiques.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2017 Annual ReportVery high reliability

Last verified: 21 September 2026

13

29 août 2017

Acquisition de Patheon

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert Patheon pour environ 7,36 Md$ dette comprise, entrant à grande échelle dans les services CDMO pharmaceutiques.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2017 Annual ReportVery high reliability

Last verified: 21 September 2026

14

31 mars 2016

Acquisition d’Affymetrix

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert Affymetrix pour environ 1,34 Md$ net de trésorerie, renforçant les outils d’analyse cellulaire et génétique.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2016 Annual ReportVery high reliability

Last verified: 21 September 2026

15

19 septembre 2016

Acquisition de FEI Company

Status not specified

Not yet available in English — French original shown.

Thermo Fisher acquiert FEI pour environ 4,08 Md$, renforçant son portefeuille de microscopie électronique haut de gamme.

Legal status — source text
completed

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2016 Annual ReportVery high reliability

Last verified: 21 September 2026

16

2014

Acquisition de Life Technologies avec remèdes antitrust

Status not specified

Not yet available in English — French original shown.

Thermo Fisher réalise l’acquisition de Life Technologies, après acceptation de remèdes imposant la cession de Dharmacon et des activités HyClone de milieux et sérums de culture cellulaire.

Sources · 1

  1. [1]
    Federal Trade CommissionFTC Puts Conditions on Thermo Fisher Acquisition of Life TechnologiesVery high reliability

Last verified: 21 September 2026

17

8 mai 2006

Accord de fusion Thermo Electron–Fisher Scientific

Status not specified

Not yet available in English — French original shown.

Thermo Electron et Fisher Scientific annoncent un rapprochement en actions visant à créer un groupe intégré de produits et services scientifiques.

Sources · 1

  1. [1]
    Thermo Fisher ScientificThermo Electron and Fisher Scientific to Combine in Industry-Transforming TransactionVery high reliability

Last verified: 21 September 2026

18

9 novembre 2006

Création de Thermo Fisher Scientific par fusion

Status not specified

Not yet available in English — French original shown.

Thermo Fisher Scientific est formé par la fusion de Thermo Electron et Fisher Scientific.

Legal status — source text
completed

Sources · 1

  1. [1]
    Thermo Fisher ScientificInvestor FAQs – formation of Thermo Fisher ScientificVery high reliability

Last verified: 21 September 2026

19

1967

Introduction en Bourse de Thermo Electron

No legal proceedings

Not yet available in English — French original shown.

Thermo Electron réalise son introduction en Bourse en 1967.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2017 Annual ReportVery high reliability

Last verified: 21 September 2026

20

1956

Constitution de Thermo Electron

No legal proceedings

Not yet available in English — French original shown.

Thermo Electron, prédécesseur juridique de Thermo Fisher, est constitué en 1956.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionThermo Fisher Scientific 2017 Annual ReportVery high reliability

Last verified: 21 September 2026

II. Constellation of documented links

Each link refers to an imported relation or to a documented mention in a profile. A documented mention does not, on its own, prove a personal relationship.

List of documented links
  1. Becton Dickinson1 reference
    • Mentioned in “Acquisition de l’activité Advanced Bioprocessing de BD” — Thermo Fisher Scientific's profile cites Becton Dickinson.
  2. QIAGEN1 reference
    • Mentioned in “Offre publique sur QIAGEN puis échec du rapprochement” — Thermo Fisher Scientific's profile cites QIAGEN.

III. Your opinion of this profile

One opinion per browser, which you can change at any time. It rates the quality of the profile, not the person.

IV. Has something changed?

A new court decision, a missing source, a mistake? Tell us what should be updated: every request is read by the editorial team.

Update request

Thermo Fisher Scientific

Say which controversy is concerned and, if possible, give a source. Between 10 and 2,500 characters.

0 / 2500